News
November 4, 2024
Our lead program, EXV-802 for the treatment of agitation in dementia associated with Alzheimer’s disease, received a Fast Track designation from the US FDA
April 1, 2024
Dr Hans Moebius, co-founder of Exciva, took over the role of a Chief Medical Officer bringing with him over thirty years of leadership in Neurology and Psychiatry drug development and translational medicine
June 1, 2023
Francisco Orellana, a seasoned professional who has worked in the biotech sector for over twenty years, joined Exciva as Chief Financial Officer
December 1, 2022
Nadine Knowles joined the Exciva team as Head of Clinical Operations. She has over thirty years of experience in operationalising clinical trials, with particular expertise in clinical studies focussing on agitation in Alzheimer's disease dementia, gained from her leadership roles at Avanir and Otsuka.
October 25, 2022
The US PTO granted a patent to Exciva for its invention of innovative composition of matter with various therapeutic uses in neuropsychiatry
October 11, 2022
Exciva successfully completed Phase I study of its proprietary EXV-802 combination of dextromethorphan and a 5-HT2A/2C receptor inverse agonist
October 26, 2021
Exciva raises €9 million in Series A round led by Andera Partners (full press release)